Publications
Filters: First Letter Of Keyword is R [Clear All Filters]
Whole-Genome and Epigenomic Landscapes of Etiologically Distinct Subtypes of Cholangiocarcinoma." Cancer Discov 7, no. 10 (2017): 1116-1135.
"Whole-Genome and Epigenomic Landscapes of Etiologically Distinct Subtypes of Cholangiocarcinoma." Cancer Discov 7, no. 10 (2017): 1116-1135.
"Variable selection for covariate-adjusted semiparametric inference in randomized clinical trials." Stat Med 31, no. 29 (2012): 3789-804.
"Variable selection for covariate-adjusted semiparametric inference in randomized clinical trials." Stat Med 31, no. 29 (2012): 3789-804.
"Using Structural Equation Modeling to Assess the Links between Tobacco Smoke Exposure, Volatile Organic Compounds, and Respiratory Function for Adolescents Aged 6 to 18 in the United States." Int J Environ Res Public Health 14, no. 10 (2017).
"Using pilot data to size a two-arm randomized trial to find a nearly optimal personalized treatment strategy." Stat Med 35, no. 8 (2016): 1245-56.
"Using pilot data to size a two-arm randomized trial to find a nearly optimal personalized treatment strategy." Stat Med 35, no. 8 (2016): 1245-56.
"Use of historical control data for assessing treatment effects in clinical trials." Pharm Stat 13, no. 1 (2014): 41-54.
"The use of Bayesian hierarchical models for adaptive randomization in biomarker-driven phase II studies." J Biopharm Stat 25, no. 1 (2015): 66-88.
"The use of Bayesian hierarchical models for adaptive randomization in biomarker-driven phase II studies." J Biopharm Stat 25, no. 1 (2015): 66-88.
"A unification of models for meta-analysis of diagnostic accuracy studies without a gold standard." Biometrics 71, no. 2 (2015): 538-47.
"A unification of models for meta-analysis of diagnostic accuracy studies without a gold standard." Biometrics 71, no. 2 (2015): 538-47.
"A unification of models for meta-analysis of diagnostic accuracy studies without a gold standard." Biometrics 71, no. 2 (2015): 538-47.
"Tximeta: Reference sequence checksums for provenance identification in RNA-seq." PLoS Comput Biol 16, no. 2 (2020): e1007664.
"Tximeta: Reference sequence checksums for provenance identification in RNA-seq." PLoS Comput Biol 16, no. 2 (2020): e1007664.
"TwinMARM: two-stage multiscale adaptive regression methods for twin neuroimaging data." IEEE Trans Med Imaging 31, no. 5 (2012): 1100-12.
"Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer (EMILIA): a descriptive analysis of final overall survival results from a randomised, open-label, phase 3 trial." Lancet Oncol 18, no. 6 (2017): 732-742.
"Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer (EMILIA): a descriptive analysis of final overall survival results from a randomised, open-label, phase 3 trial." Lancet Oncol 18, no. 6 (2017): 732-742.
"Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer (EMILIA): a descriptive analysis of final overall survival results from a randomised, open-label, phase 3 trial." Lancet Oncol 18, no. 6 (2017): 732-742.
"Translational studies of phenotypic probes for the mononuclear phagocyte system and liposomal pharmacology." J Pharmacol Exp Ther 347, no. 3 (2013): 599-606.
"Translational studies of phenotypic probes for the mononuclear phagocyte system and liposomal pharmacology." J Pharmacol Exp Ther 347, no. 3 (2013): 599-606.
"Translational studies of phenotypic probes for the mononuclear phagocyte system and liposomal pharmacology." J Pharmacol Exp Ther 347, no. 3 (2013): 599-606.
"Translational Breast Cancer Research Consortium (TBCRC) 022: A Phase II Trial of Neratinib for Patients With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer and Brain Metastases." J Clin Oncol 34, no. 9 (2016): 945-52.
"Toxicity Related to Radiotherapy Dose and Targeting Strategy: A Pooled Analysis of Cooperative Group Trials of Combined Modality Therapy for Locally Advanced Non-Small Cell Lung Cancer." J Thorac Oncol 14, no. 2 (2019): 298-303.
"Toxicity Related to Radiotherapy Dose and Targeting Strategy: A Pooled Analysis of Cooperative Group Trials of Combined Modality Therapy for Locally Advanced Non-Small Cell Lung Cancer." J Thorac Oncol 14, no. 2 (2019): 298-303.
"Toxicity Related to Radiotherapy Dose and Targeting Strategy: A Pooled Analysis of Cooperative Group Trials of Combined Modality Therapy for Locally Advanced Non-Small Cell Lung Cancer." J Thorac Oncol 14, no. 2 (2019): 298-303.
"Time-dependent classification accuracy curve under marker-dependent sampling." Biom J 58, no. 4 (2016): 974-92.
"Tests of trend between disease outcomes and ordinal covariates discretized from underlying continuous variables: simulation studies and applications to NHANES 2007-2008." BMC Med Res Methodol 19, no. 1 (2019): 2.
"Testing and estimation in marker-set association study using semiparametric quantile regression kernel machine." Biometrics 72, no. 2 (2016): 364-71.
"Ten-year experience with extended criteria cardiac transplantation." Circ Heart Fail 6, no. 6 (2013): 1230-8.
"Systematic review and network meta-analysis comparing palbociclib with chemotherapy agents for the treatment of postmenopausal women with HR-positive and HER2-negative advanced/metastatic breast cancer." Breast Cancer Res Treat 166, no. 1 (2017): 167-177.
"Systematic review and network meta-analysis comparing palbociclib with chemotherapy agents for the treatment of postmenopausal women with HR-positive and HER2-negative advanced/metastatic breast cancer." Breast Cancer Res Treat 166, no. 1 (2017): 167-177.
"Systematic review and network meta-analysis comparing palbociclib with chemotherapy agents for the treatment of postmenopausal women with HR-positive and HER2-negative advanced/metastatic breast cancer." Breast Cancer Res Treat 166, no. 1 (2017): 167-177.
"Systematic review and network meta-analysis comparing palbociclib with chemotherapy agents for the treatment of postmenopausal women with HR-positive and HER2-negative advanced/metastatic breast cancer." Breast Cancer Res Treat 166, no. 1 (2017): 167-177.
"Systematic review and network meta-analysis comparing palbociclib with chemotherapy agents for the treatment of postmenopausal women with HR-positive and HER2-negative advanced/metastatic breast cancer." Breast Cancer Res Treat 166, no. 1 (2017): 167-177.
"SynthEx: a synthetic-normal-based DNA sequencing tool for copy number alteration detection and tumor heterogeneity profiling." Genome Biol 18, no. 1 (2017): 66.
"Swimming downstream: statistical analysis of differential transcript usage following Salmon quantification." F1000Res 7 (2018): 952.
"Survival Benefit of Lung Transplantation in the Modern Era of Lung Allocation." Ann Am Thorac Soc 14, no. 2 (2017): 172-181.
"Survival Benefit of Lung Transplantation in the Modern Era of Lung Allocation." Ann Am Thorac Soc 14, no. 2 (2017): 172-181.
"Superiority of combining two independent trials in interim futility analysis." Stat Methods Med Res 29, no. 2 (2020): 522-540.
"Subgroup detection and sample size calculation with proportional hazards regression for survival data." Stat Med 36, no. 29 (2017): 4646-4659.
"Studying gene and gene-environment effects of uncommon and common variants on continuous traits: a marker-set approach using gene-trait similarity regression." Am J Hum Genet 89, no. 2 (2011): 277-88.
"Statistical methods for multivariate meta-analysis of diagnostic tests: An overview and tutorial." Stat Methods Med Res 25, no. 4 (2016): 1596-619.
"Statistical issues for design and analysis of single-arm multi-stage phase II cancer clinical trials." Contemp Clin Trials 42 (2015): 9-17.
"Statistical issues and advances in cancer precision medicine research." J Biopharm Stat 28, no. 2 (2018): 215-216.
"Statistical design of noninferiority multiple region clinical trials to assess global and consistent treatment effects." J Biopharm Stat 27, no. 6 (2017): 933-944.
"Statistical Considerations for Subgroup Analyses." J Thorac Oncol 16, no. 3 (2021): 375-380.
"Statistical aspect of translational and correlative studies in clinical trials." Chin Clin Oncol 5, no. 1 (2016): 11.
"Single-nucleotide resolution analysis of nucleotide excision repair of ribosomal DNA in humans and mice." J Biol Chem 294, no. 1 (2019): 210-217.
"Single-nucleotide resolution analysis of nucleotide excision repair of ribosomal DNA in humans and mice." J Biol Chem 294, no. 1 (2019): 210-217.
"Simulation of brain mass effect with an arbitrary Lagrangian and Eulerian FEM." Med Image Comput Comput Assist Interv 13, no. Pt 2 (2010): 274-81.
"A simple and robust method for multivariate meta-analysis of diagnostic test accuracy." Stat Med 36, no. 1 (2017): 105-121.
"A simple and accurate method to determine genomewide significance for association tests in sequencing studies." Genet Epidemiol 43, no. 4 (2019): 365-372.
"Sequential multiple assignment randomization trials with enrichment design." Biometrics 73, no. 2 (2017): 378-390.
"Sequential multiple assignment randomization trials with enrichment design." Biometrics 73, no. 2 (2017): 378-390.
"Sensitivity analysis for missing outcomes in time-to-event data with covariate adjustment." J Biopharm Stat 26, no. 2 (2016): 269-79.
"Semiparametric regression for the weighted composite endpoint of recurrent and terminal events." Biostatistics 17, no. 2 (2016): 390-403.
"Semiparametric regression analysis of interval-censored data with informative dropout." Biometrics 74, no. 4 (2018): 1213-1222.
"Semiparametric regression analysis of interval-censored competing risks data." Biometrics 73, no. 3 (2017): 857-865.
"Semiparametric regression analysis of interval-censored competing risks data." Biometrics 73, no. 3 (2017): 857-865.
"Semiparametric inference for a two-stage outcome-dependent sampling design with interval-censored failure time data." Lifetime Data Anal 26, no. 1 (2020): 85-108.
"Semiparametric inference for a 2-stage outcome-auxiliary-dependent sampling design with continuous outcome." Biostatistics 12, no. 3 (2011): 521-34.
"Semiparametric estimation of treatment effect with time-lagged response in the presence of informative censoring." Lifetime Data Anal 17, no. 4 (2011): 566-93.
"Semiparametric additive marginal regression models for multiple type recurrent events." Lifetime Data Anal 18, no. 4 (2012): 504-27.
"Semiparametric additive marginal regression models for multiple type recurrent events." Lifetime Data Anal 18, no. 4 (2012): 504-27.
"Selection of the initial design for the two-stage continual reassessment method." J Biopharm Stat 27, no. 3 (2017): 495-506.
"Secondary outcome analysis for data from an outcome-dependent sampling design." Stat Med 37, no. 15 (2018): 2321-2337.
"Secondary analysis of case-control association studies: Insights on weighting-based inference motivate a new specification test." Stat Med 39, no. 22 (2020): 2869-2882.
"Seamless Phase IIa/IIb and enhanced dose-finding adaptive design." J Biopharm Stat 26, no. 5 (2016): 912-23.
"SCOPE: A Normalization and Copy-Number Estimation Method for Single-Cell DNA Sequencing." Cell Syst 10, no. 5 (2020): 445-452.e6.
"Sample size/power calculation for stratified case-cohort design." Stat Med 33, no. 23 (2014): 3973-85.
"Sample size/power calculation for stratified case-cohort design." Stat Med 33, no. 23 (2014): 3973-85.
"Sample size estimation in educational intervention trials with subgroup heterogeneity in only one arm." Stat Med 32, no. 12 (2013): 2140-54.
"Sample size estimation in educational intervention trials with subgroup heterogeneity in only one arm." Stat Med 32, no. 12 (2013): 2140-54.
"Sample size considerations of prediction-validation methods in high-dimensional data for survival outcomes." Genet Epidemiol 37, no. 3 (2013): 276-82.
"Sample size calculation for cluster randomization trials with a time-to-event endpoint." Stat Med 39, no. 25 (2020): 3608-3623.
"Sample size calculation for cluster randomization trials with a time-to-event endpoint." Stat Med 39, no. 25 (2020): 3608-3623.
"Sample size calculation for cluster randomization trials with a time-to-event endpoint." Stat Med 39, no. 25 (2020): 3608-3623.
"SAFE-clustering: Single-cell Aggregated (from Ensemble) clustering for single-cell RNA-seq data." Bioinformatics 35, no. 8 (2019): 1269-1277.
"ROC curve estimation under test-result-dependent sampling." Biostatistics 14, no. 1 (2013): 160-72.
"Robust test method for time-course microarray experiments." BMC Bioinformatics 11 (2010): 391.
"Robust regression for optimal individualized treatment rules." Stat Med 38, no. 11 (2019): 2059-2073.
"A robust method for estimating optimal treatment regimes." Biometrics 68, no. 4 (2012): 1010-8.
"Risk calculators are useful but..." J Thorac Cardiovasc Surg 151, no. 3 (2016): 706-707.
"Reporting and Guidelines in Propensity Score Analysis: A Systematic Review of Cancer and Cancer Surgical Studies." J Natl Cancer Inst 109, no. 8 (2017).
"Reporting and Guidelines in Propensity Score Analysis: A Systematic Review of Cancer and Cancer Surgical Studies." J Natl Cancer Inst 109, no. 8 (2017).
"Reinforcement learning strategies for clinical trials in nonsmall cell lung cancer." Biometrics 67, no. 4 (2011): 1422-33.
"A regularized variable selection procedure in additive hazards model with stratified case-cohort design." Lifetime Data Anal 24, no. 3 (2018): 443-463.
"Regression analysis for secondary response variable in a case-cohort study." Biometrics 74, no. 3 (2018): 1014-1022.
"Recent progresses in outcome-dependent sampling with failure time data." Lifetime Data Anal 23, no. 1 (2017): 57-82.
"Recent progresses in outcome-dependent sampling with failure time data." Lifetime Data Anal 23, no. 1 (2017): 57-82.
"Receiver operating characteristic curves and confidence bands for support vector machines." Biometrics 77, no. 4 (2021): 1422-1430.
"The rapid enrollment design for Phase I clinical trials." Stat Med 35, no. 15 (2016): 2516-24.
"Rapid enrollment design for finding the optimal dose in immunotherapy trials with ordered groups." J Biopharm Stat 29, no. 4 (2019): 625-634.
"Randomized phase II clinical trials." J Biopharm Stat 24, no. 4 (2014): 802-16.
"Randomized, double-blind study comparing proposed biosimilar LA-EP2006 with reference pegfilgrastim in breast cancer." Future Oncol 12, no. 11 (2016): 1359-67.
"Racial Differences in Diffusion of Intensity-Modulated Radiation Therapy for Localized Prostate Cancer." Am J Mens Health 10, no. 5 (2016): 399-407.
"Racial Differences in Diffusion of Intensity-Modulated Radiation Therapy for Localized Prostate Cancer." Am J Mens Health 10, no. 5 (2016): 399-407.
"Proportional hazards model with a change point for clustered event data." Biometrics 73, no. 3 (2017): 835-845.
"Probability-enhanced sufficient dimension reduction for binary classification." Biometrics 70, no. 3 (2014): 546-55.
"